clear erlenmeyer flask on the table

Brussels, Belgium Eurofins Discovery, a leading figure in the drug discovery research landscape and a key component of the Eurofins laboratory network, has today announced the introduction of its groundbreaking platform, DiscoveryAI SAFIRE. This Suite of ADMET Predictions For In Silico Refinement and Evaluation (SAFIRE) represents a significant leap in the field, utilizing advanced artificial intelligence (AI) and machine learning (ML) techniques.

A New Era in Drug Discovery: AI-Powered Predictions

The SAFIRE platform is a testament to Eurofins Discovery’s commitment to innovation in drug discovery. By integrating proprietary datasets with the prowess of AI and ML, SAFIRE offers unprecedented capabilities in expediting the discovery process. This advanced platform has been designed to enhance the prediction of ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties of molecules, which is a crucial aspect of drug development.

Groundbreaking Results: Enhanced Accuracy and Efficiency

Eurofins Discovery’s research has yielded impressive results, demonstrating the potential of AI advances in drug discovery. The models developed under the SAFIRE platform, trained with exclusive BioPrint database data and augmented with publicly available datasets, have shown remarkable improvements in performance. The application of these advanced models has resulted in Matthews Correlation Coefficient values exceeding 0.4 and accuracy rates surpassing 80%. These metrics indicate a significant enhancement in the efficiency and precision of predicting ADMET properties, a core element in the development of new drugs.

Expanding the Chemical Space: Broadening Horizons

One of the key achievements of the SAFIRE platform is its ability to broaden the chemical space covered by the models. This expansion ensures a more comprehensive approach to drug discovery, enabling researchers to explore a wider range of chemical compounds. The integration of AI and ML not only speeds up the discovery process but also provides a more nuanced understanding of a larger array of molecules.

Ackermans & van Haaren Reports Mixed Results in 2023 Amid Market Challenges

Eurofins Discovery: At the Forefront of Drug Research Innovation

The launch of the SAFIRE platform places Eurofins Discovery at the forefront of technological advancements in drug research. With its unique combination of proprietary data, cutting-edge AI, and ML capabilities, Eurofins Discovery is poised to make significant contributions to the field of drug discovery, ultimately benefiting the broader medical and scientific communities.

Conclusion: A Promising Future for Drug Discovery

The introduction of the DiscoveryAI SAFIRE platform marks a significant milestone in the evolution of drug discovery research. Eurofins Discovery’s innovative approach, blending AI and ML with specialized datasets, promises to transform the landscape of drug research, offering faster, more accurate predictions, and paving the way for the development of new, effective medicinal compounds.

By Lisa Luckas

Lisa Luckas is a Sr. Business News Editor at Nobot.News.

Leave a Reply

Your email address will not be published. Required fields are marked *

GDPR Cookie Consent with Real Cookie Banner